Frequently Asked Questions
Factors such as awareness about Shigella infection and increasing shigella infection are acting as the major drivers for the global shigella diarrhoea prophylaxis market.
Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Aurobindo Pharma (India), Mylan N.V. (U.S.), Sagent Pharmaceuticals, Inc (U.S.), Lupin (India), Wockhardt (India), Hikma Pharmaceutical Plc (U.K.), Akorn Incorporated (U.S.).
The Shigella Diarrhoea Prophylaxis Market segments covered in this report are By Treatment (Antibiotics, Fluid and Salt Replacement, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy).
